Tocilizumab levels in treated rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at how much tocilizumab (an injected biologic) stays in your blood. It aims to understand why some patients respond better and to help guide dosing. If you have rheumatoid arthritis that's mild or in remission and are already scheduled for this treatment, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rheumatoid arthritis (diagnosed by a doctor).
- Your arthritis is under good control — it's mild or in remission.
- You are scheduled to receive a specific dose (8 mg per kg of body weight) of tocilizumab (a biologic medicine) by infusion.
- You've already tried other arthritis drugs (like methotrexate or other biologics) and they didn't work well enough.
- You're not being treated with tocilizumab for another condition, and you haven't had diverticulitis or a bowel perforation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This study tests different targeted treatments for adults with rheumatoid arthritis who have already tried other biologic or targeted medications and need a new option. It aims to find which treatment works best for people like you.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.